Free Trial

Lantern Pharma (LTRN) Competitors

Lantern Pharma logo
$3.15 0.00 (0.00%)
As of 09:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LTRN vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLF

Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

Lantern Pharma vs. Its Competitors

Lantern Pharma (NASDAQ:LTRN) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Lantern Pharma has higher earnings, but lower revenue than Fate Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$20.78M-$1.84-1.71
Fate Therapeutics$13.63M9.96-$186.26M-$1.49-0.80

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lantern Pharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Lantern Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -83.26% -70.65%
Fate Therapeutics -1,318.93%-47.17%-34.60%

Lantern Pharma presently has a consensus price target of $25.00, indicating a potential upside of 693.65%. Fate Therapeutics has a consensus price target of $3.83, indicating a potential upside of 223.49%. Given Lantern Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Lantern Pharma is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fate Therapeutics
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13

Lantern Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

In the previous week, Fate Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Fate Therapeutics and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.89 beat Fate Therapeutics' score of 0.53 indicating that Lantern Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Lantern Pharma Very Positive
Fate Therapeutics Positive

Summary

Fate Therapeutics beats Lantern Pharma on 8 of the 14 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LTRN vs. The Competition

MetricLantern PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$33.90M$2.85B$5.48B$8.94B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-1.7121.1726.2219.74
Price / SalesN/A262.85394.92109.12
Price / CashN/A41.8936.4957.06
Price / Book1.617.237.915.37
Net Income-$20.78M-$55.05M$3.15B$248.34M
7 Day Performance1.29%-0.60%0.75%1.67%
1 Month Performance-1.25%3.77%3.46%4.56%
1 Year Performance-28.41%2.20%34.60%18.42%

Lantern Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LTRN
Lantern Pharma
2.287 of 5 stars
$3.15
flat
$25.00
+693.7%
-30.3%$33.90MN/A-1.7120Positive News
Gap Down
FATE
Fate Therapeutics
4.0733 of 5 stars
$1.14
-4.2%
$3.83
+236.3%
-65.0%$136.38M$13.63M-0.77550Gap Down
KYTX
Kyverna Therapeutics
1.5834 of 5 stars
$3.22
+4.9%
$18.50
+474.5%
-64.5%$132.68M$7.03M-0.9596
BDTX
Black Diamond Therapeutics
3.2188 of 5 stars
$2.27
-2.6%
$14.60
+543.2%
-47.2%$132.49MN/A37.8390Positive News
Analyst Forecast
VXRT
Vaxart
2.3389 of 5 stars
$0.56
-3.4%
$3.00
+435.3%
-33.2%$132.42M$28.70M-2.08120Positive News
Gap Up
LXEO
Lexeo Therapeutics
2.1492 of 5 stars
$3.96
+1.3%
$16.60
+319.2%
-73.0%$129.80M$650K-1.2058
LYEL
Lyell Immunopharma
3.2739 of 5 stars
$8.99
+3.5%
$20.00
+122.5%
-70.2%$128.68M$60K-0.36270
BYSI
BeyondSpring
N/A$2.74
-13.6%
N/A-2.0%$127.80M$1.75M0.0080High Trading Volume
NMRA
Neumora Therapeutics
2.524 of 5 stars
$0.75
-5.1%
$9.29
+1,144.7%
-92.0%$127.08MN/A-0.46108Positive News
Gap Up
NKTX
Nkarta
2.2414 of 5 stars
$1.75
-1.4%
$14.33
+721.4%
-70.8%$125.60MN/A-1.16140News Coverage
FTLF
FitLife Brands
4.375 of 5 stars
$12.99
-2.5%
$20.50
+57.8%
-14.3%$125.09M$64.47M15.4620

Related Companies and Tools


This page (NASDAQ:LTRN) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners